Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus

被引：0
作者：
Anca D. Askanase
George J. Wan
Mary P. Panaccio
Enxu Zhao
Julie Zhu
Roman Bilyk
Richard A. Furie
机构：
[1] Columbia University Irving Medical Center,
[2] Mallinckrodt Pharmaceuticals,undefined
[3] Zucker School of Medicine at Hofstra/Northwell,undefined
来源：
Rheumatology and Therapy | 2021年 / 8卷
关键词：
Acthar Gel; Autoimmune disease; Glucocorticoid; Patient-reported outcomes; Repository corticotropin injection; Systemic lupus erythematosus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：573 / 584
页数：11
相关论文
共 50 条
  • [1] Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar(R) Gel) for Persistently Active Systemic Lupus Erythematosus
    Askanase, Anca D.
    Wan, George J.
    Panaccio, Mary P.
    Zhao, Enxu
    Zhu, Julie
    Bilyk, Roman
    Furie, Richard A.
    RHEUMATOLOGY AND THERAPY, 2021, 8 (01) : 573 - 584
  • [2] Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus
    Askanase, Anca D.
    Wright, Dale
    Zhao, Enxu
    Zhu, Julie
    Bilyk, Roman
    Furie, Richard A.
    RHEUMATOLOGY AND THERAPY, 2021, 8 (04) : 1871 - 1886
  • [3] Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus
    Anca D. Askanase
    Dale Wright
    Enxu Zhao
    Julie Zhu
    Roman Bilyk
    Richard A. Furie
    Rheumatology and Therapy, 2021, 8 : 1871 - 1886
  • [4] Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
    Anca D. Askanase
    Enxu Zhao
    Julie Zhu
    Roman Bilyk
    Richard A. Furie
    Rheumatology and Therapy, 2020, 7 : 893 - 908
  • [5] Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
    Askanase, Anca D.
    Zhao, Enxu
    Zhu, Julie
    Bilyk, Roman
    Furie, Richard A.
    RHEUMATOLOGY AND THERAPY, 2020, 7 (04) : 893 - 908
  • [6] Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis
    Mehdi Mirsaeidi
    Robert P. Baughman
    Debasis Sahoo
    Eva Tarau
    Pulmonary Therapy, 2023, 9 : 237 - 253
  • [7] Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis
    Mirsaeidi, Mehdi
    Baughman, Robert P.
    Sahoo, Debasis
    Tarau, Eva
    PULMONARY THERAPY, 2023, 9 (02) : 237 - 253
  • [8] Acthar Gel (repository corticotropin injection) for persisten5tly active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial
    Askanase, Anca D.
    Zhao, Enxu
    Zhu, Julie
    Connolly-Strong, Erin
    Furie, Richard A.
    LUPUS SCIENCE & MEDICINE, 2020, 7 (01):
  • [9] Pneumococcal vaccination in patients with systemic lupus erythematosus: A multicenter placebo-controlled randomized double-blind study
    Grabar, Sophie
    Groh, Matthieu
    Bahuaud, Mathilde
    Le Guern, Veronique
    Costedoat-Chalumeau, Nathalie
    Mathian, Alexis
    Hanslik, Thomas
    Guillevin, Loic
    Batteux, Frederic
    Launay, Odile
    VACCINE, 2017, 35 (37) : 4877 - 4885
  • [10] Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus
    Tam, LS
    Li, EK
    Wong, CK
    Lam, CWK
    Szeto, CC
    LUPUS, 2004, 13 (08) : 601 - 604
12345